Results 1 to 10 of about 35,596 (239)
PharmVar GeneFocus: CYP2C9 [PDF]
Clinical Pharmacology & Therapeutics, 2021 The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti‐inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin ...
Sangkuhl, Katrin +14 more
openaire +3 more sources
Functional characterization of the defective CYP2C9 variant CYP2C9*18 [PDF]
Pharmacology Research & Perspectives, 2021 AbstractCytochrome P450 2C9 (CYP2C9) is one of the most important drugs metabolizing enzymes and accounts for the metabolism of about 13%–17% of clinical drugs. Like other members in CYP2 family, CYP2C9 gene exhibits great genetic polymorphism among different races and individuals. CYP2C9*18 is one CYP2C9 allelic variant identified in a Southeast Asian
Jian Liu +11 more
openaire +3 more sources
CYP2C9 polymorphisms and CYP2C9*2 genotyping primers [PDF]
British Journal of Clinical Pharmacology, 2002 The primers first suggested by Wang et al.[1] for the genotyping of the CYP2C9 Arg144Cys mutation were based on the gene structure of CYP2C9 prior to knowledge of the gene structure of the closely related CYP2C19. Early studies cannot be faulted for using these primers, since the gene structure of CYP2C19 was not known.
openaire +1 more source
CYP2C9 Genetic Polymorphisms and Warfarin [PDF]
Clinical and Applied Thrombosis/Hemostasis, 2004 The objective of this study was to report 2 cases of CYP2C9 genetic polymorphism and elevated warfarin S: R ratios in patients taking low doses of warfarin, and compare the observed characteristics with those in published reports. Two patients of different age groups and races were evaluated for CYP2C9 genotype and warfarin S: R ratios.
Andrea R, Redman +5 more
openaire +2 more sources
High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid® Substrates [PDF]
SLAS Discovery, 2004 CYP2C9 is a genetically polymorphic human cytochrome P450 isozyme involved in the oxidative metabolism of many drugs, including nonsteroidal anti-inflammatory compounds. Individuals genotyped heterozygous or homozygous for CYP2C9 allelic variants have demonstrated altered metabolism of some drugs primarily metabolized by CYP2C9.
Bryan D, Marks +3 more
openaire +2 more sources
Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype [PDF]
Antimicrobial Agents and Chemotherapy, 2006 Voriconazole, a broad-spectrum triazole antifungal agent, is well absorbed, with a high oral bioavailability of 96% (6). Maximal plasma concentrations are observed 1 to 2 h after drug administration. The volume of distribution is estimated to be 4.6 liters/kg, and the plasma protein binding is 58%.
Marcus J P, Geist +3 more
openaire +2 more sources
CYP2C9*2 and CYP2C9*3 Alleles Confer a Lower Risk for Myocardial Infarction [PDF]
Clinical Chemistry, 2004 Cytochrome P-450 (CYP) genes encode for membrane-bound, heme-containing enzymes that catalyze the oxidation of various drugs and endogenous substrates such as vitamin D, steroids, or fatty acids, including arachidonic acid (AA). CYP enzymes of the P-450 2C9 subfamily are produced in the liver, are responsible for 50% of the epoxygenase activity in ...
Marion, Funk +6 more
openaire +2 more sources